Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04878432 · ClinicalTrials.gov registry record · Phase 2
STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 39
- Enrollment target
NCT04878432 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 39 participants.
The verdict
NCT04878432, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 39 participants
- Enrollment target
Study Summary
The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).
Interventions
- DRUG Azacitidine
- DRUG Decitabine
- DRUG MBG453
- DRUG INQOVI (oral decitabine)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 39 participants |
| Start Date | 2022-03-17 |
| Est. Completion | 2024-09-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04878432
The ClinicalTrials.gov registry entry for NCT04878432 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 39 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 4 interventions - of which Azacitidine is the first listed.
NCT04878432 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04878432 about?
NCT04878432 is a clinical study titled "STIMULUS MDS-US : Sabatolimab Added to HMA in Higher Risk MDS". The main objective of this study was to assess the safety profile of MBG453 (sabatolimab) in combination with FDA approved hypomethylating agents (HMAs) of investigator's choice (IV Decitabine or Azacitidine /SC Azacitidine /Oral Decitabine (cedazuridine combination (INQOVI))).
What is the current status of trial NCT04878432?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 39 participants. The study started on 2022-03-17. Estimated completion is 2024-09-01.
What interventions are being tested in trial NCT04878432?
The interventions under investigation include: Azacitidine (DRUG), Decitabine (DRUG), MBG453 (DRUG), INQOVI (oral decitabine) (DRUG).
Who is sponsoring clinical trial NCT04878432?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.